SCHEMBL5754376

SCHEMBL5754376

O=C(c1ccc2sc(-c3ccccc3O)nc2c1)N1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.51
HPGD P15428 8/20 0.50
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TSHR P16473 1/20 0.49
TP53 P04637 1/20 0.48
TRPM8 Q7Z2W7 2/20 0.47
PLA2G7 Q13093 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
KDM4E B2RXH2 1/20 0.46
MAPT P10636 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
S1PR1 P21453 2/20 0.44
FASN P49327 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5756224 0.91 HPGD (0.55) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL5755144 0.86 POLB (0.52) POLBHPGDNPC1RAB9ATSHR
SCHEMBL5757212 0.77 S1PR1 (0.54) POLBHPGDNPC1RAB9ASMN1; SMN2
SCHEMBL5755711 0.77 MAPT (0.49) POLBNPC1RAB9ASMN1; SMN2TRPM8
SCHEMBL5757497 0.76 S1PR1 (0.55) POLBHPGDNPC1RAB9ATSHR
SCHEMBL5758013 0.76 HPGD (0.52) POLBHPGDNPC1RAB9ATSHR
SCHEMBL5759089 0.76 HPGD (0.52) POLBHPGDNPC1RAB9ATSHR
SCHEMBL5757116 0.75 PDCD1 (0.50) NPC1RAB9AKDM4EMAPTNPSR1
SCHEMBL5755318 0.75 MAPK1 (0.60) HPGDNPC1RAB9ASMN1; SMN2TSHR
SCHEMBL5755675 0.74 HPGD (0.52) HPGDNPC1RAB9ATSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1539723-B1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2006-05-24 EP claimed
US-20060106015-A1 Novel use of benzothiazole derivatives ASTRAZENECA (SE) 2006-05-18 US claimed
EP-1539723-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES AstraZeneca AB (SE) 2005-06-15 EP claimed
WO-2004016600-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-02-26 WO claimed
EP-1539723-B1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2006-05-24 EP disclosed
US-20060106015-A1 Novel use of benzothiazole derivatives ASTRAZENECA (SE) 2006-05-18 US disclosed
EP-1539723-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES AstraZeneca AB (SE) 2005-06-15 EP disclosed
WO-2004016600-A1 NOVEL USE OF BENZOTHIAZOLE DERIVATIVES ASTRAZENECA AB (SE) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106015-A1 Novel use of benzothiazole derivatives ITK, WEE2, WEE1 POLB 1104/4885HPGD 905/4885NPC1 2627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.